A Phase I Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 Following Repeat Dose Administration in Participants With Overweight or Obesity
Latest Information Update: 19 Feb 2025
At a glance
- Drugs AZD-6234 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 11 Feb 2025 Planned number of patients changed from 76 to 142.
- 11 Feb 2025 Planned End Date changed from 30 Apr 2025 to 4 Feb 2026.
- 11 Feb 2025 Planned primary completion date changed from 30 Apr 2025 to 4 Feb 2026.